TY - JOUR
T1 - Combined high-sensitivity copeptin and troponin T evaluation for the diagnosis of non-ST elevation acute coronary syndrome in the emergency department
AU - Alquézar, Aitor
AU - Santaló, Miguel
AU - Rizzi, Miguel
AU - Gich, Ignasi
AU - Grau, Margarita
AU - Sionis, Alessandro
AU - Ordóñez-Llanos, Jordi
AU - Mercé, Javier
AU - Martin, Alfonso
AU - Muñoz, Mar
AU - Povar, Javier
AU - Velilla, Joaquín
AU - Calmarza, Pilar
AU - Temboury, Francisco
AU - Ortiz, Carmen
AU - Balaguer, José
AU - Carratalá, Arturo
PY - 2017/1/1
Y1 - 2017/1/1
N2 - © 2017, Grupo Saned. All rights reserved. Objectives. To assess the diagnostic yield of a high-sensitivity copeptin (hs-copep) assay alone or in combination with a high-sensitivity cardiac troponin T (hs-cTnt) assay for the diagnosis of non-ST segment elevation acute coronary syndrome (NSTEMI) in patients with chest pain in the emergency department (ED). The secondary aim was to assess the 1-year prognostic utility of these biomarkers in this clinical context. Material and methods. Retrospective observational study of a series of patients attended for chest pain suggesting myocardial ischemia in 5 Spanish ED. The first blood drawn in the ED was used for hs-copep and hs-cTnt assays, which were processed in a single laboratory serving all centers. Diagnostic utility was assessed by sensitivity, specificity, positive and negative predictive values and likelihood ratios, and the area under the receiver operating characteristic curve (ROC). We also performed a separate analysis with data for the subgroup of patients with early detection of symptoms (3 h of onset of symptoms). We recorded complications, mortality or reinfarction occurring within a year of the index event. Results. We included 297 patients; 63 (21.2%) with NSTEMI. The median age was 69 years (interquartile range, 70–76 years), and 199 (67%) were men. The ROC was 0.89 (95% CI, 0.85–0.94) for the hs-cTnt assay, 0.58 (95% CI, 0.51–0.66) for the hs-copep assay, and 0.90 (95% CI, 0.86–0.94) for the 2 assays combined. The ROC for the 2 assays combined was not significantly better than the ROC for the hs-cTnt by itself (P=.89). We saw the same pattern of results when we analyzed the subgroup of patients who presented early. Sixty percent of the complications occurred in patients with elevated findings on both assays. Elevated hs-copep findings did not provide prognostic information that was not already provided by hs-cTnt findings (P=.56). Conclusion. The hs-copep assay does not increase the diagnostic or prognostic yield already provided by the hs-cTnt assay in patients suspected of myocardial infarction in the ED.
AB - © 2017, Grupo Saned. All rights reserved. Objectives. To assess the diagnostic yield of a high-sensitivity copeptin (hs-copep) assay alone or in combination with a high-sensitivity cardiac troponin T (hs-cTnt) assay for the diagnosis of non-ST segment elevation acute coronary syndrome (NSTEMI) in patients with chest pain in the emergency department (ED). The secondary aim was to assess the 1-year prognostic utility of these biomarkers in this clinical context. Material and methods. Retrospective observational study of a series of patients attended for chest pain suggesting myocardial ischemia in 5 Spanish ED. The first blood drawn in the ED was used for hs-copep and hs-cTnt assays, which were processed in a single laboratory serving all centers. Diagnostic utility was assessed by sensitivity, specificity, positive and negative predictive values and likelihood ratios, and the area under the receiver operating characteristic curve (ROC). We also performed a separate analysis with data for the subgroup of patients with early detection of symptoms (3 h of onset of symptoms). We recorded complications, mortality or reinfarction occurring within a year of the index event. Results. We included 297 patients; 63 (21.2%) with NSTEMI. The median age was 69 years (interquartile range, 70–76 years), and 199 (67%) were men. The ROC was 0.89 (95% CI, 0.85–0.94) for the hs-cTnt assay, 0.58 (95% CI, 0.51–0.66) for the hs-copep assay, and 0.90 (95% CI, 0.86–0.94) for the 2 assays combined. The ROC for the 2 assays combined was not significantly better than the ROC for the hs-cTnt by itself (P=.89). We saw the same pattern of results when we analyzed the subgroup of patients who presented early. Sixty percent of the complications occurred in patients with elevated findings on both assays. Elevated hs-copep findings did not provide prognostic information that was not already provided by hs-cTnt findings (P=.56). Conclusion. The hs-copep assay does not increase the diagnostic or prognostic yield already provided by the hs-cTnt assay in patients suspected of myocardial infarction in the ED.
KW - Acute myocardial infarction
KW - Diagnosis
KW - High-sensitivity cardiac troponin T assay
KW - High-sensitivity copeptin
KW - Prognosis
M3 - Article
SN - 1137-6821
VL - 29
SP - 237
EP - 244
JO - Emergencias
JF - Emergencias
IS - 4
ER -